Dec 20, 2024 | Defective Drugs, Defective Product, Product Liability, Tepezza Injuries
Tepezza (teprotumumab) has gained attention as a groundbreaking treatment for Thyroid Eye Disease (TED), a rare autoimmune condition that causes inflammation and tissue expansion around the eyes. Approved by the U.S. Food and Drug Administration (FDA) in 2020, Tepezza...
Oct 28, 2024 | Defective Drugs, Defective Product, Product Liability, Tepezza Injuries
Tepezza, a medication originally intended to treat thyroid eye disease (TED), has recently been linked to serious hearing complications, including permanent hearing loss, tinnitus, and other auditory issues. Although Tepezza was granted fast-track approval by the FDA...
Aug 20, 2024 | Defective Drugs, Defective Medical Device, Defective Product, Product Liability, Tepezza Injuries
Tepezza (teprotumumab-trbw) is a breakthrough medication used to treat thyroid eye disease (TED), a rare condition that causes inflammation and bulging of the eyes. Tepezza was approved by the U.S. Food and Drug Administration (FDA) in January 2020 and has been...
Aug 6, 2024 | Defective Drugs, Defective Product, Medical News, Product Liability
Tepezza (teprotumumab) has emerged as a groundbreaking treatment for Thyroid Eye Disease (TED), a condition that can cause bulging eyes, double vision, and other serious issues. While Tepezza has offered hope to many patients, it has also raised concerns due to...
